US8303944B2
(en)
*
|
2006-08-11 |
2012-11-06 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7659270B2
(en)
|
2006-08-11 |
2010-02-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8329159B2
(en)
*
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7745636B2
(en)
|
2006-08-11 |
2010-06-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20100055071A1
(en)
*
|
2006-11-21 |
2010-03-04 |
Martin Robert Leivers |
Anti-Viral Compounds
|
US7741347B2
(en)
|
2007-05-17 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
ES2601856T3
(es)
|
2007-06-08 |
2017-02-16 |
Mannkind Corporation |
Inhibidores de la IRE-1A
|
US7728027B2
(en)
*
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
EP2250163B1
(fr)
*
|
2008-02-12 |
2012-03-28 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
WO2009102694A1
(fr)
|
2008-02-12 |
2009-08-20 |
Bristol-Myers Squibb Company |
Dérivés hétérocycliques inhibiteurs du virus de l'hépatite c
|
JP5312486B2
(ja)
*
|
2008-02-13 |
2013-10-09 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
US8147818B2
(en)
*
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7704992B2
(en)
*
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7906655B2
(en)
|
2008-08-07 |
2011-03-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8383094B2
(en)
|
2008-10-01 |
2013-02-26 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8729077B2
(en)
*
|
2008-11-28 |
2014-05-20 |
Glaxosmithkline Llc |
Anti-viral compounds, compositions, and methods of use
|
CN104163816A
(zh)
*
|
2008-12-03 |
2014-11-26 |
普雷西迪奥制药公司 |
Hcv ns5a的抑制剂
|
SG171890A1
(en)
*
|
2008-12-03 |
2011-07-28 |
Presidio Pharmaceuticals Inc |
Inhibitors of hcv ns5a
|
RU2505539C2
(ru)
|
2008-12-23 |
2014-01-27 |
Эбботт Лэборетриз |
Антивирусные соединения
|
JP2012513409A
(ja)
*
|
2008-12-23 |
2012-06-14 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
EP2210882A1
(fr)
*
|
2009-01-16 |
2010-07-28 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Synthèse de nouvelle azahistidine protégée, ses procédés et utilisations dans la synthèse
|
US8314135B2
(en)
*
|
2009-02-09 |
2012-11-20 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole antivirals
|
US8188132B2
(en)
|
2009-02-17 |
2012-05-29 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
US8420686B2
(en)
|
2009-02-17 |
2013-04-16 |
Enanta Pharmaceuticals, Inc. |
Linked diimidazole antivirals
|
US8637561B2
(en)
*
|
2009-02-17 |
2014-01-28 |
Enanta Pharmaceuticals, Inc. |
Linked diimidazole derivatives
|
US8394968B2
(en)
|
2009-02-17 |
2013-03-12 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8242156B2
(en)
|
2009-02-17 |
2012-08-14 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
TWI438200B
(zh)
|
2009-02-17 |
2014-05-21 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
CN102427731B
(zh)
|
2009-02-27 |
2015-05-13 |
英安塔制药有限公司 |
丙型肝炎病毒抑制剂
|
US8101643B2
(en)
|
2009-02-27 |
2012-01-24 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
US8673954B2
(en)
|
2009-02-27 |
2014-03-18 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
US9765087B2
(en)
|
2009-02-27 |
2017-09-19 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
US8426458B2
(en)
|
2009-02-27 |
2013-04-23 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C Virus inhibitors
|
US8507522B2
(en)
|
2009-03-06 |
2013-08-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8709999B2
(en)
|
2009-03-27 |
2014-04-29 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic HCV inhibitors
|
EP2410843A4
(fr)
*
|
2009-03-27 |
2012-08-08 |
Presidio Pharmaceuticals Inc |
Inhibiteurs à noyaux fusionnés de l'hépatite c
|
TWI476190B
(zh)
*
|
2009-03-30 |
2015-03-11 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
US8796466B2
(en)
*
|
2009-03-30 |
2014-08-05 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TW201038559A
(en)
*
|
2009-04-09 |
2010-11-01 |
Bristol Myers Squibb Co |
Hepatitis C virus inhibitors
|
US8143414B2
(en)
|
2009-04-13 |
2012-03-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010120935A1
(fr)
*
|
2009-04-15 |
2010-10-21 |
Abbott Laboratories |
Composés antiviraux
|
JP5582662B2
(ja)
|
2009-05-13 |
2014-09-03 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗ウイルス化合物
|
US8211928B2
(en)
*
|
2009-05-29 |
2012-07-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8138215B2
(en)
|
2009-05-29 |
2012-03-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2435424B1
(fr)
|
2009-05-29 |
2015-01-21 |
Merck Sharp & Dohme Corp. |
Composés antiviraux de trois fractions d'aryle liées pour traiter des maladies telles que l'hépatite c
|
US8937150B2
(en)
*
|
2009-06-11 |
2015-01-20 |
Abbvie Inc. |
Anti-viral compounds
|
US9394279B2
(en)
|
2009-06-11 |
2016-07-19 |
Abbvie Inc. |
Anti-viral compounds
|
AU2012203474B2
(en)
*
|
2009-06-11 |
2014-09-18 |
Abbvie Ireland Unlimited Company |
Anti-Viral Compounds
|
US8716454B2
(en)
|
2009-06-11 |
2014-05-06 |
Abbvie Inc. |
Solid compositions
|
MY186633A
(en)
*
|
2009-06-11 |
2021-07-31 |
Abbvie Bahamas Ltd |
Heterocyclic compounds as inhibitors of hepatitis c virus (hcv)
|
US8221737B2
(en)
|
2009-06-16 |
2012-07-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8609648B2
(en)
|
2009-07-02 |
2013-12-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
WO2011004276A1
(fr)
*
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Inhibiteurs du virus de lhépatite c
|
MX2012000695A
(es)
|
2009-07-16 |
2012-06-12 |
Vertex Pharma |
Análogos de bencimidazol para el tratamiento o la prevención de infecciones por flavivirus.
|
US8344155B2
(en)
|
2009-09-04 |
2013-01-01 |
Glaxosmith Kline Llc |
Chemical compounds
|
US8822700B2
(en)
*
|
2009-09-11 |
2014-09-02 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8927709B2
(en)
|
2009-09-11 |
2015-01-06 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8815928B2
(en)
|
2009-09-11 |
2014-08-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8759332B2
(en)
*
|
2009-09-11 |
2014-06-24 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
EP2475254A4
(fr)
*
|
2009-09-11 |
2013-05-22 |
Enanta Pharm Inc |
Inhibiteurs du virus de l'hépatite c
|
US9156818B2
(en)
|
2009-09-11 |
2015-10-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8703938B2
(en)
*
|
2009-09-11 |
2014-04-22 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US20110274648A1
(en)
|
2009-11-11 |
2011-11-10 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110269956A1
(en)
|
2009-11-11 |
2011-11-03 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110281910A1
(en)
|
2009-11-12 |
2011-11-17 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
JP2013512246A
(ja)
|
2009-11-25 |
2013-04-11 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
|
US20110137633A1
(en)
*
|
2009-12-03 |
2011-06-09 |
Abbott Laboratories |
Anti-viral compounds and methods of identifying the same
|
US8415482B2
(en)
*
|
2009-12-04 |
2013-04-09 |
National Health Research Institutes |
Proline derivatives
|
WO2011081918A1
(fr)
|
2009-12-14 |
2011-07-07 |
Enanta Pharmaceuticals, Inc |
Inhibiteurs du virus de l'hépatite c
|
US8377980B2
(en)
|
2009-12-16 |
2013-02-19 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN104530079B
(zh)
*
|
2009-12-18 |
2017-10-20 |
北京凯因科技股份有限公司 |
C型肝炎病毒复制的新型抑制剂
|
MY159958A
(en)
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
WO2011087740A1
(fr)
|
2009-12-22 |
2011-07-21 |
Schering Corporation |
Composés tricycliques fusionnés et leurs méthodes d'utilisation pour le traitement de maladies virales
|
US8362020B2
(en)
|
2009-12-30 |
2013-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8933110B2
(en)
|
2010-01-25 |
2015-01-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8785487B2
(en)
|
2010-01-25 |
2014-07-22 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8623814B2
(en)
*
|
2010-02-23 |
2014-01-07 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
US8178531B2
(en)
*
|
2010-02-23 |
2012-05-15 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
CA2791630A1
(fr)
|
2010-03-04 |
2011-09-09 |
Enanta Pharmaceuticals, Inc. |
Agents pharmaceutiques combinatoires au titre d'inhibiteurs de la replication du vhc
|
AU2011224698A1
(en)
*
|
2010-03-09 |
2012-11-01 |
Merck Sharp & Dohme Corp. |
Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
|
JP2013522375A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
EP2555622A4
(fr)
|
2010-04-09 |
2013-09-18 |
Enanta Pharm Inc |
Inhibiteurs du virus de l'hépatite c
|
WO2011149856A1
(fr)
*
|
2010-05-24 |
2011-12-01 |
Presidio Pharmaceuticals, Inc. |
Inhibiteurs de ns5a du vhc
|
US8778938B2
(en)
|
2010-06-04 |
2014-07-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
WO2011154871A1
(fr)
*
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Inhibiteurs du virus de l'hépatite c
|
NZ605440A
(en)
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
WO2012006060A1
(fr)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Composés et méthodes de traitement ou de prévention d'infections à flavovirus
|
CA2803248A1
(fr)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Composes et methodes pour le traitement ou la prevention d'infections par flavivirus
|
CA2805440A1
(fr)
|
2010-07-26 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Composes de biphenylene substitue et procedes d'utilisation desdits composes pour le traitement de maladies virales
|
EA023642B1
(ru)
*
|
2010-07-26 |
2016-06-30 |
Янссен Сайенсиз Айрлэнд Юси |
Гетеробициклические производные в качестве ингибиторов hcv
|
EP2603080A4
(fr)
|
2010-08-12 |
2014-01-22 |
Enanta Pharm Inc |
Inhibiteurs du virus de l'hépatite c
|
JP2013534249A
(ja)
|
2010-08-17 |
2013-09-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス科ウイルス感染の処置または予防のための化合物および方法
|
CA2809261A1
(fr)
|
2010-08-26 |
2012-03-01 |
Rfs Pharma, Llc |
Inhibiteurs puissants et selectifs du virus de l'hepatite c
|
US8822520B2
(en)
|
2010-09-22 |
2014-09-02 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic HCV inhibitors
|
US8999967B2
(en)
|
2010-09-29 |
2015-04-07 |
Presidio Pharmaceuticals, Inc. |
Tricyclic fused ring inhibitors of hepatitis C
|
EP2621279B1
(fr)
|
2010-09-29 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Dérivés tétracycliques condensés et procédés d'utilisation de ceux-ci dans le traitement de maladies virales
|
WO2012048013A2
(fr)
*
|
2010-10-06 |
2012-04-12 |
Inhibitex, Inc. |
Dérivés phosphorodiamidate de composés nucléosidiques à base de guanosine destinés à traiter des infections virales
|
AU2014203655B2
(en)
*
|
2010-10-13 |
2016-07-07 |
Abbvie Ireland Unlimited Company |
Anti-viral compounds
|
PE20140109A1
(es)
|
2010-10-26 |
2014-02-23 |
Presidio Pharmaceuticals Inc |
Inhibidores del virus de la hepatitis c
|
CA3095528C
(fr)
|
2010-11-17 |
2023-07-18 |
Gilead Pharmasset Llc |
Composes antiviraux
|
RU2452735C1
(ru)
*
|
2010-11-30 |
2012-06-10 |
Александр Васильевич Иващенко |
Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
|
WO2012083053A2
(fr)
*
|
2010-12-15 |
2012-06-21 |
Abbott Laboratories |
Composés anti-viraux
|
EP2651928A4
(fr)
*
|
2010-12-15 |
2014-06-18 |
Abbvie Inc |
Composés anti-viraux
|
US9173887B2
(en)
|
2010-12-22 |
2015-11-03 |
Abbvie Inc. |
Hepatitis C inhibitors and uses thereof
|
US8552047B2
(en)
|
2011-02-07 |
2013-10-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9546160B2
(en)
*
|
2011-05-12 |
2017-01-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
CN103687489A
(zh)
|
2011-05-18 |
2014-03-26 |
埃南塔制药公司 |
制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
|
WO2013016499A1
(fr)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Procédés de préparation de composés du thiophène
|
TW201317223A
(zh)
|
2011-07-26 |
2013-05-01 |
Vertex Pharma |
噻吩化合物
|
WO2013030750A1
(fr)
|
2011-09-01 |
2013-03-07 |
Lupin Limited |
Composés antiviraux
|
US20140378416A1
(en)
|
2011-09-14 |
2014-12-25 |
Michael P. Dwyer |
Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
|
MD4589C1
(ro)
|
2011-09-16 |
2019-03-31 |
Gilead Pharmasset Llc |
Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
|
EA037883B1
(ru)
|
2011-11-16 |
2021-05-31 |
Джилид Фармассет Ллс |
Противовирусные соединения
|
CN104203940B
(zh)
|
2011-12-28 |
2017-01-18 |
爱尔兰詹森科学公司 |
作为hcv抑制剂的杂双环衍生物
|
US9034832B2
(en)
|
2011-12-29 |
2015-05-19 |
Abbvie Inc. |
Solid compositions
|
US9326973B2
(en)
|
2012-01-13 |
2016-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
IN2014MN01547A
(fr)
|
2012-02-10 |
2015-05-08 |
Lupin Ltd |
|
US9012427B2
(en)
|
2012-03-22 |
2015-04-21 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
AR090699A1
(es)
|
2012-04-18 |
2014-12-03 |
Biocryst Pharm Inc |
Compuestos inhibidores de la actividad de la arn polimerasa viral
|
US20130309196A1
(en)
|
2012-05-16 |
2013-11-21 |
Gilead Sciences, Inc. |
Antiviral compounds
|
EA029081B9
(ru)
|
2013-01-31 |
2018-09-28 |
Джилид Фармассет Ллс |
Комбинированный состав двух противовирусных соединений
|
WO2014134251A1
(fr)
|
2013-02-28 |
2014-09-04 |
Vertex Pharmaceuticals Incorporated |
Compositions pharmaceutiques
|
US11484534B2
(en)
|
2013-03-14 |
2022-11-01 |
Abbvie Inc. |
Methods for treating HCV
|
US9717712B2
(en)
|
2013-07-02 |
2017-08-01 |
Bristol-Myers Squibb Company |
Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
|
US20150023913A1
(en)
|
2013-07-02 |
2015-01-22 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US9775831B2
(en)
|
2013-07-17 |
2017-10-03 |
Bristol-Myers Squibb Company |
Combinations comprising biphenyl derivatives for use in the treatment of HCV
|
CA2921160C
(fr)
|
2013-08-27 |
2021-04-13 |
Gilead Pharmasset Llc |
Preparation combinee de deux composes antiviraux
|
WO2015065817A1
(fr)
|
2013-10-30 |
2015-05-07 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphes d'un inhibiteur de la protéine ns5a du vhc et leurs utilisations
|
WO2015089810A1
(fr)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Composés tétracycliques hétérocycliques condensés et leurs procédés d'utilisation pour le traitement de maladies virales
|
EP3089757A1
(fr)
|
2014-01-03 |
2016-11-09 |
AbbVie Inc. |
Formes galéniques antivirales solides
|
TWI721947B
(zh)
|
2014-06-11 |
2021-03-21 |
美商基利法瑪席特有限責任公司 |
抗病毒化合物的固態形式
|
US10301358B2
(en)
|
2015-06-29 |
2019-05-28 |
Collagen Medical, LLC |
Collagen imaging compositions
|
WO2017023631A1
(fr)
|
2015-08-06 |
2017-02-09 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
RU2650610C1
(ru)
|
2017-02-28 |
2018-04-16 |
Васильевич Иващенко Александр |
Противовирусная композиция и способ ее применения
|
BR112020016466A2
(pt)
|
2018-02-13 |
2020-12-15 |
Gilead Sciences, Inc. |
Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1, para tratar câncer e para aprimorar a função de células-t em pacientes com hepatite b crônica (chb), e, kit para tratar ou prevenir câncer ou uma doença ou condição.
|
US10899735B2
(en)
|
2018-04-19 |
2021-01-26 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
CA3103286C
(fr)
|
2018-07-13 |
2023-05-09 |
Gilead Sciences, Inc. |
Inhibiteurs de pd-1/pd-l1
|
AU2019366355B2
(en)
|
2018-10-24 |
2022-10-13 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
WO2020117849A1
(fr)
|
2018-12-04 |
2020-06-11 |
Bristol-Myers Squibb Company |
Procédés d'analyse utilisant une courbe d'étalonnage dans un échantillon par surveillance de réaction d'isotopologues multiples
|